Skip to content

Psychosocial Treatment for Improving Chances of Survival in Women With Breast Cancer

Psychosocial Treatment Effects on Cancer Survival

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00226928
Enrollment
125
Registered
2005-09-27
Start date
Unknown
Completion date
2005-07-31
Last updated
2013-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stage IIIB, IV, Recurrent, and Metastatic Breast Cancer

Brief summary

This study will investigate the influence of psychosocial treatment on psychological outcomes and survival among women with metastatic or recurrent breast cancer.

Detailed description

The objective of this study is to investigate the influence of psychosocial treatment on psychological outcomes and survival among women with metastatic/recurrent breast cancer.

Interventions

BEHAVIORALSupportive-Expressive Group Therapy plus education
BEHAVIORALEducation

Sponsors

National Institute of Mental Health (NIMH)
CollaboratorNIH
Stanford University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Women were eligible for the study if they had documented metastatic or recurrent breast cancer, were proficient enough in English to be able to complete questionnaires and participate in a support group, were living in the Greater San Francisco Bay Area, and had a Karnofsky score of at least 70%.19

Exclusion criteria

Women were excluded if they had any of the following risk factors: positive supraclavicular lymph nodes as the only metastatic lesion at the time of initial diagnosis; active non-breast cancers within the past 10 years; or other concurrent medical conditions likely to influence short-term survival. Basal cell or squamous cell carcinomas of the skin, in situ cancer of the cervix, or melanoma with a Breslow depth less than 0.76 mm were allowed.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026